SCHEMBL4507545

SCHEMBL4507545

CCOC(=O)c1sc2nc(Cc3ccc(F)c(F)c3)[nH]c(=O)c2c1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.67
MEN1 O00255 5/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
PIP4K2A P48426 1/20 0.61
LMNA P02545 2/20 0.60
RXFP1 Q9HBX9 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
KCNH2 Q12809 1/20 0.60
ALDH1A1 P00352 5/20 0.57
KDM4E B2RXH2 5/20 0.54
HPGD P15428 3/20 0.54
MAPK1 P28482 2/20 0.54
USP2 O75604 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TP53 P04637 1/20 0.53
MAPT P10636 4/20 0.52
PKM P14618 1/20 0.52
GAA P10253 2/20 0.51
PPARG P37231 1/20 0.48
NCOA2 Q15596 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4505873 0.91 KMT2A (0.64) KMT2AMEN1L3MBTL1PIP4K2ALMNA
SCHEMBL4506212 0.89 KMT2A (0.61) KMT2AMEN1L3MBTL1PIP4K2ALMNA
SCHEMBL4514873 0.89 KMT2A (0.67) KMT2AMEN1L3MBTL1PIP4K2ALMNA
SCHEMBL3492123 0.87 MAPT (0.57) KMT2AMEN1L3MBTL1ALDH1A1KDM4E
SCHEMBL4514858 0.87 KMT2A (0.67) KMT2AMEN1L3MBTL1PIP4K2ALMNA
SCHEMBL4518554 0.87 KMT2A (0.68) KMT2AMEN1L3MBTL1PIP4K2ALMNA
SCHEMBL4519704 0.86 KMT2A (0.79) KMT2AMEN1L3MBTL1PIP4K2ALMNA
SCHEMBL4519850 0.86 KMT2A (0.66) KMT2AMEN1L3MBTL1PIP4K2ALMNA
SCHEMBL4515674 0.86 KMT2A (0.65) KMT2AMEN1L3MBTL1PIP4K2ALMNA
SCHEMBL4514505 0.86 KMT2A (0.65) KMT2AMEN1L3MBTL1PIP4K2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 KMT2A 2650/4885MEN1 2509/4885L3MBTL1 602/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 KMT2A 2650/4885MEN1 2509/4885L3MBTL1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.